web analytics

Decision Diagnostics Corp (OTCMKTS: DECN) Heats Up as GenViro International Launch Looms

0

Decision Diagnostics Corp (OTCMKTS: DECN) is heating up after the Company recently set a launch date of its International version GenViro! Covid-19 Saliva Swift Kit for September 26, 2020. DECN has notified its Korean manufacturing partner that it will place an initial order for 100,000 kits on that day. As of that same day DECN will accept orders from International distributors. The first shipments are expected to be sent to India with an initial order for 50,000 kits. The company will wholesale the International GenViro! Swift Kits at an introductory price of $8.95.  The Genviro! Covid-19 Saliva Swift Kits have undergone rigorous testing at the Company’s facility in Daegu Korea. The kits are planned in 5 languages: Spanish, French, German, Russian and English and will include 3 GenViro! Swift test strips, a saliva capture vessel and universal interface adapter and a link to an instructional video.

DECN is getting noticed by investors as its Genviro! Covid-19 Saliva Swift Kits continue to gain serious traction. The screening kit is timely, simple to use, and cost effective instant test that provides results in as little as 10 seconds, based on a small finger prick blood sample. As the world continues to reopen there is a massive need for rapid testing – widespread, affordable, accurate and accessible testing.  Antibody tests and nasal swabs are both invasive and take up to weeks for results. DECN many have the solution with its GenViro(TM) Corona Virus Screening Kit.

DECN to Launch Its International Version GenViro! Saliva Swift :10.5 Second  Covid-19 Kits on September 26, Will Then Accept Orders from Its Asian  Distributor | BioSpaceDecision Diagnostics Corp (OTCMKTS: DECN) is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. The company’s new GenViro!™ product designed to test for Covid-19, is not yet available in the United States or Puerto Rico, but Emergency (EUA) Waivers are in process with the U.S. FDA. Decision Diagnostics has submitted two applications with the FDA for a Covid-19 testing technology that identify the virus in ten (10) seconds or less. The company has been in discussions with the FDA on final testing protocols since mid-April.)

GenViro(TM) Corona Virus Screening Kit has been getting picked up by main stream media with CBS New York coverfing it in a segment called: Max Minute: Diabetes Company’s Affordable, Fast Coronavirus Test May Be Key To Reopening Businesses. According to the segment: – “We’re the product of choice because it works, it works fast and because it’s affordable….

To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DECNIn a recent update DECN CEO Keith Berman stated: “As the experts have pointed out, the country needs to change its testing platform in order to identify people when they are most infectious, and while at the same time potentially being asymptomatic, and that’s what our Genviro! Saliva testing products are designed to do. Important advancements have been made toward selecting a lab, or perhaps two labs, to do our US-based testing on our saliva methodology that we believe should be more readily accepted by the FDA, and eventually by individuals for at-home use as it is completely non-invasive. We have engaged a special consultant to expedite this process, and as a result he recently introduced us to a third laboratory located on the east coast. Our decision is now between two laboratories associated with major university hospitals and a third reference laboratory currently involved in its own (non-competitive) EUA in process. All three laboratories deal with saliva based methods. The two laboratories associated with university hospitals already have approved EUAs through the FDA. However, none of these laboratories offer methodologies that provide results as expeditiously as our GenViro! Swift Kit that has recorded lab test results in (10.5 seconds), and, even more significantly, offer true point of care testing. As discussed previously, the GenViro! Swift Kit will be tested in two phases; the first phase providing results to assist the company in seeking approval in the EU, Russian Federation and the ten other nations where we have signed distributor agreements. The second phase testing will be for the FDA EUA authorization.

On the September 26 launch date of its International version GenViro! Covid-19 Saliva Swift Kit CEO Keith Berman stated:

“While we continue to seek our FDA authorization, we are immediately working with our Asian distributor to fulfill the first International order of at least 50,000 GenViro Swift Kits, and to secure additional orders as quickly as possible. With Covid-19 again rising dramatically in India, and with two failed attempts to address testing needs with kits previously ordered by Indian entities, the plan by our distributor to send the first international GenViro! Swift Kits to India could not come at a better time for that hard hit country. While we anticipate US FDA approval, we recognize that the rest of the world can use the benefits Genviro! provides. Our international distributors will be responsible for capturing any certifications or approvals required to produce sales and we look forward to working with distributors around the globe to quickly bring this accurate, affordable, simple and scalable testing solution to market.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently running northbound DECN is an exciting story in small caps that has runner in its blood and a history of dynamic moves. GenViro(TM) Corona Virus Screening Kit is gaining serious traction as it provides results in as little as 10.5 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19.  The instant test is not yet available in the United States or Puerto Rico, but Emergency (EUA) Waivers are in process with the U.S. FDA. DECN has submitted two applications with the FDA for its Covid-19 testing technology. DECN recently set a launch date of its International version GenViro! Covid-19 Saliva Swift Kit for September 26, 2020. DECN has notified its Korean manufacturing partner that it will place an initial order for 100,000 kits on that day. As of that same day DECN will accept orders from International distributors. The first shipments are expected to be sent to India with an initial order for 50,000 kits. We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.

Share.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.